Clinical Trial Update: Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of a recombinant birch pollen allergen for allergic rhinoconjunctivitis due to birch pollen. The study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Birch Pollen Allergy

Drugs mentioned

• Recombinant birch pollen allergen

Snippet

Sponsor: Allergopharma GmbH & Co. KG | Conditions: Birch Pollen Allergy | Phase 3 | Status: COMPLETED